ArticleJHEP reports : innovation in hepatology2026
Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsPrevious studies have demonstrated that the pattern of progression (POP) following systemic therapy or transarterial radioembolisation is prognostic for post-progression overall survival (PPOS). POP has therefore been proposed as a stratification factor for subsequent clinical trials. However, its significance in TACE-treated populations has not been prospectively explored. We analysed the impact of POP on PPOS in patients treated in the TACE-2 and TACTICS trials.
methodsTACE-2 and TACTICS are two prospective, multicentre, randomised trials comparing TACE plus sorafenib with TACE plus placebo, conducted in the UK and Japan, respectively. Patients with radiological progression in both trials were included in this analysis. POP was defined as: target or non-target lesion progression (TNTLP), new intrahepatic lesions (NIH), or new extrahepatic lesions (NEH). As extrahepatic disease was an exclusion criterion in both trials, only intrahepatic lesions qualified for the TNTLP group. PPOS was assessed using the Kaplan-Meier method, and comparisons were performed using the log-rank test.
resultsA total of 285 patients were included (86 with TNTLP, 167 with NIH, and 32 with NEH). Median PPOS was 24.8 months for TNTLP, 18.7 months for NIH, and 7.0 months for NEH. Compared with the TNTLP group, patients with NEH had significantly worse survival (adjusted hazard ratio 3.05, 95% CI 1.88-4.94; p <0.001), whereas survival in the NIH group was not significantly different (adjusted hazard ratio 1.21, 95% CI 0.88-1.65; p = 0.24). No survival differences were observed between placebo and sorafenib arms within each POP group.
conclusionProgression in the form of new extrahepatic disease following TACE occurred in only 11% of patients but was associated with poor overall survival, reinforcing the importance of extrahepatic disease as a stratification factor in clinical trials. IMPACT AND IMPLICATIONS: Pattern of progression has been validated as a significant independent prognostic factor for post-progression overall survival in patients with hepatocellular carcinoma (HCC) treated with systemic anticancer therapies and selective internal radiation therapy. This study is the first prospective multicentre analysis to demonstrate that pattern of progression is also a significant independent prognostic factor for post-progression overall survival in patients with HCC treated with transarterial chemoembolisation. Future trials of locoregional therapies for HCC should report pattern of progression and consider its use as a stratification factor in subsequent studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.